Bvf Cut Its Holding in Chemocentryx (CCXI) as Stock Price Rose; Parsley Energy (PE) Valuation Declined While Syntal Capital Partners Has Upped Position

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Syntal Capital Partners Llc increased its stake in Parsley Energy Inc (PE) by 130.77% based on its latest 2018Q4 regulatory filing with the SEC. Syntal Capital Partners Llc bought 154,398 shares as the company’s stock declined 8.14% while stock markets rallied. The institutional investor held 272,464 shares of the energy company at the end of 2018Q4, valued at $4.35M, up from 118,066 at the end of the previous reported quarter. Syntal Capital Partners Llc who had been investing in Parsley Energy Inc for a number of months, seems to be bullish on the $5.81B market cap company. The stock increased 3.03% or $0.54 during the last trading session, reaching $18.34. About 5.07M shares traded. Parsley Energy, Inc. (NYSE:PE) has declined 24.67% since March 18, 2018 and is downtrending. It has underperformed by 29.04% the S&P500. Some Historical PE News: 04/05/2018 – PARSLEY ENERGY SAYS 85% OF ITS OIL LEAVING PERMIAN BY PIPE; 04/05/2018 – PARSLEY EXPECTS ROYALTY BURDEN IN DELAWARE BASIN TO FALL 10%; 03/05/2018 – Parsley Energy 1Q Adj EPS 31c; 03/05/2018 – PARSLEY ENERGY SAYS ON APRIL 30, CO, UNITS ENTERED INTO SIXTH AMENDMENT TO CREDIT AGREEMENT DATED AS OF OCT 28, 2016 – SEC FILING; 28/03/2018 – CORRECTED-Parsley Energy will not add rigs if oil prices rise further -CEO; 04/05/2018 – PARSLEY ENERGY EXECUTIVES COMMENTING DURING CONFERENCE CALL; 03/05/2018 – PARSLEY ENERGY INC PE.N -QTRLY TOTAL NET PRODUCTION AVERAGED 93.4 MBOE PER DAY VS 54.78 MBOE PER DAY; 03/05/2018 – PARSLEY ENERGY SAYS AMENDMENT INCREASES BORROWING BASE UNDER CREDIT AGREEMENT FROM $1.8 BLN TO $2.3 BLN, AMONG OTHER THINGS; 04/05/2018 – PARSLEY CEO: SPIN-OFF OF MINERAL UNIT `SOMETHING TO LOOK INTO’; 03/05/2018 – PARSLEY ENERGY 1Q ADJ EPS 31C, EST. 24C

Bvf Inc decreased its stake in Chemocentryx Inc (CCXI) by 1.27% based on its latest 2018Q4 regulatory filing with the SEC. Bvf Inc sold 86,237 shares as the company’s stock rose 6.99% with the market. The hedge fund held 6.69M shares of the health care company at the end of 2018Q4, valued at $72.96M, down from 6.77M at the end of the previous reported quarter. Bvf Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $566.70 million market cap company. The stock increased 5.54% or $0.59 during the last trading session, reaching $10.78. About 1.25M shares traded or 289.82% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since March 18, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En

More recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” on March 11, 2019. Also Globenewswire.com published the news titled: “New Research: Key Drivers of Growth for Ellie Mae, Spotify Technology SA, Bristow Group, Teradata, ChemoCentryx, and AgroFresh Solutions — Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” on February 26, 2019. Seekingalpha.com‘s news article titled: “ChemoCentryx terminates previously announced common stock offering – Seeking Alpha” with publication date: September 28, 2018 was also an interesting one.

Bvf Inc, which manages about $999.89M and $765.19M US Long portfolio, upped its stake in Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) by 116,941 shares to 1.88 million shares, valued at $12.83M in 2018Q4, according to the filing. It also increased its holding in Molecular Templates Inc by 576,792 shares in the quarter, for a total of 3.36 million shares, and has risen its stake in Vbi Vaccines Inc.

Since October 16, 2018, it had 0 insider purchases, and 8 insider sales for $87.64 million activity. On Thursday, January 10 the insider Cappel Markus J. sold $74,079. 7.34 million shares valued at $85.85 million were sold by GLAXOSMITHKLINE PLC on Tuesday, October 16. Schall Thomas J. also sold $242,370 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) shares.

Investors sentiment decreased to 0.93 in 2018 Q4. Its down 0.05, from 0.98 in 2018Q3. It dived, as 7 investors sold CCXI shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Millennium Limited Liability stated it has 16,813 shares or 0% of all its holdings. Alps Advsrs has 156,559 shares for 0.01% of their portfolio. Gp One Trading Lp reported 13,165 shares or 0% of all its holdings. Zebra Capital Management Lc owns 14,396 shares. Moreover, Century Cos has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 65,787 shares. 333,917 were reported by Geode Cap Management Limited Liability. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment Corp holds 37,000 shares. Trexquant Invest LP accumulated 33,717 shares or 0.02% of the stock. Raymond James & Assoc owns 12,174 shares for 0% of their portfolio. 81,534 were reported by Matarin Mgmt. Legal And General Public Ltd Com stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 30,596 are owned by Rhumbline Advisers. Bvf Il owns 6.69M shares or 9.54% of their US portfolio. Product Limited Liability Com accumulated 19,469 shares or 0.01% of the stock. Bb&T Ltd Llc accumulated 114,827 shares.

Since November 27, 2018, it had 5 buys, and 0 insider sales for $270,057 activity. ALAMEDDINE A R had bought 1,000 shares worth $20,000 on Friday, November 30. The insider Brokmeyer Ron bought 1,000 shares worth $19,990.

Investors sentiment is 1.32 in 2018 Q4. Its the same as in 2018Q3. It has no change, as 56 investors sold PE shares while 76 reduced holdings. only 52 funds opened positions while 122 raised stakes. 252.80 million shares or 1.53% more from 248.99 million shares in 2018Q3 were reported. Waddell And Reed Financial owns 1.49M shares for 0.07% of their portfolio. Jbf Capital Inc invested in 0% or 35,000 shares. State Street reported 7.79 million shares stake. Magnetar Ltd Liability Corporation has 1.08M shares. Charles Schwab Inv Management accumulated 0.01% or 1.11M shares. Viking Fund Ltd Llc reported 405,000 shares. Public Employees Retirement Association Of Colorado reported 0% in Parsley Energy, Inc. (NYSE:PE). Amp Capital Limited owns 0.02% invested in Parsley Energy, Inc. (NYSE:PE) for 152,582 shares. Icon Advisers owns 637,617 shares for 1.07% of their portfolio. Motco has invested 0.02% in Parsley Energy, Inc. (NYSE:PE). Sumitomo Mitsui Asset Limited holds 0% or 13,295 shares in its portfolio. Brandywine Global Inv Mngmt Ltd Limited Liability Company reported 0% of its portfolio in Parsley Energy, Inc. (NYSE:PE). Sei Investments invested 0.01% of its portfolio in Parsley Energy, Inc. (NYSE:PE). Meeder Asset Management owns 844 shares for 0% of their portfolio. Vanguard accumulated 23.88M shares.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *